Floatz logo

Inalimarev

Metastatic Cancer

Michael Morse, MDvaccinePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

276 Active assets in the Metastatic Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Inalimarev is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic acinar cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →